IMMUNE CELLS ASSAY TO PREDICT C-PEPTIDE LOSS (DSB.AD001.056)

Thematic area

Biomedical sciences

Project area

Structure responsible for the research project

Institute Experimental Endocrinology and Oncology "Gaetano Salvatore" (IEOS)

Project manager

MARIO GALGANI
Phone number: 0817464580
Email: mario.galgani@unina.it

Abstract

Type 1 Diabetes (T1D) is an autoimmune disease characterized by a T cell-mediated destruction of pancreatic b-cells. Immune cell subsets and circulating biological compounds at the interface between immune and metabolic pathways are considered to be involved in the progression of b-cell failure. To date, few studies have investigated the involvement of metabolic/inflammatory factors in the early stages of T1D. In addition, none of the previously mentioned studies examined inflammatory/metabolic and immune parameters able to predict residual b-cell function over time and monitor the metabolic and immunological status characterizing the disease. In our previous study We identified a specific meta-immunological profile associated to disease status and immune cell populations able to predict residual cell function over time. Our proposal aims at verifying the internal precision of our assay (citofluorimetric analysis of CD3+CD16+CD56+ T cells and CD1c+CD19-CD14-CD303- type 1 mDC1s), through the analysis of blinded replicated testing in collaboration with Core and Validation Center (CAV) at Benaroya Research Institute (Seattle, USA).

Goals

Confermare la validità e la precisione interna di un saggio biologico che prevede l'analisi di due specifiche popolazioni del sangue periferico: i linfociti CD3+CD16+CD56+ e le cellule dendritiche mieloidi di tipo 1 CD1c+CD19-CD14-CD303- .

Start date of activity

01/08/2015

Keywords

TYPE 1 DIABETES, BIOMARKERS, IMMUNE RESPONSE

Last update: 04/12/2023